$Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH$

Biotech

Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH

December 12, 2022

« 1 … 12 13 14 15 16 … 557 »

SEARCH FOR AN ARTICLE

best biotech stocks

ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV(TM) & BIVIGAM®

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SolarEdge, Eiger, Unisys, and Rent and Encourages Investors to Contact the Firm

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting

Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR) Encourages Long-Term EIGR Investors to Contact the Firm

(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation

Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH

LATEST NEWS